Tempus ECG-AF vs OMRON VitalSight
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your objective is to proactively identify elderly patients at increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm is specifically designed for patients aged 65 or older without pre-existing AF, utilizing standard 12-lead ECG recordings to support earlier identification and follow-up.
View Tempus ECG-AF →Choose OMRON VitalSight if…
Choose OMRON VitalSight if you need a comprehensive remote patient monitoring solution for managing hypertension. This service is ideal for physicians looking to provide patients with at-home connected blood pressure monitors that securely integrate data with EHRs, enabling continuous oversight and timely intervention for out-of-range readings.
View OMRON VitalSight →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | OMRON VitalSight |
|---|---|---|
| Pricing | Contact vendor | Reimbursement-based |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based (physician dashboard) with at-home patient devices. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
OMRON VitalSightOMRON VitalSight offers a 'plug-and-play' experience for patients with pre-set devices delivered directly to their homes, and its data hub operates without requiring Wi-Fi or cellular connection, significantly enhancing patient accessibility and ease of use. While Tempus ECG-AF integrates into existing facility systems, OMRON's focus on out-of-the-box usability for both patients and clinicians gives it an edge.
Clinical Value
Tempus ECG-AFTempus ECG-AF provides a unique and highly impactful predictive capability, using an FDA-cleared AI algorithm to identify patients at increased risk of developing new-onset Atrial Fibrillation within 12 months. This enables proactive intervention for a condition with serious complications. While OMRON VitalSight offers valuable continuous management for hypertension, Tempus's predictive diagnostic innovation holds greater potential for preventative impact.
Pricing & Value
OMRON VitalSightOMRON VitalSight explicitly states 'no setup or device costs for physicians' and 'generally little to no cost to the patient,' significantly reducing financial barriers to adoption for both providers and patients. Although Tempus ECG-AF has a defined Medicare reimbursement rate, it lacks the same transparency regarding upfront costs, making OMRON's value proposition clearer and more accessible.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). Both integrate into healthcare workflows, with Tempus ECG-AF integrating into facility systems and OMRON VitalSight offering EHR/EMR integration and a cloud-based dashboard. Given their regulatory compliance and integration capabilities from established companies, neither tool definitively outperforms the other in this dimension.
Innovation
Tempus ECG-AFTempus ECG-AF's core innovation is its FDA-cleared AI algorithm that analyzes standard 12-lead ECGs to predict the future risk of AF, representing a significant advancement in predictive diagnostics for cardiovascular disease. While OMRON VitalSight offers innovative features for remote patient monitoring accessibility, Tempus's predictive AI capability for a new-onset condition is a more groundbreaking application of artificial intelligence in clinical care.
Support & Docs
OMRON VitalSightOMRON VitalSight provides comprehensive support for both clinicians and patients, including complete patient technical support, device setup assistance, and help with billing for clinics. The direct-to-home, pre-set patient kits imply a robust and accessible support ecosystem. Tempus offers clinician-focused support via phone and email, but OMRON's holistic approach, particularly for the patient-facing aspects of RPM, gives it an edge.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | OMRON VitalSight |
|---|---|---|
| Name | Tempus ECG-AF | OMRON VitalSight |
| Company | Tempus AI, Inc. | OMRON Healthcare |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Remote patient monitoring service for US physicians, offering connected blood pressure monitors and data hubs that securely integrate with EHRs to manage hypertension and improve patient outcomes. |
| Primary Function | AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months. | Remote blood pressure monitoring and hypertension management. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and OMRON VitalSight.